Chromoendoscopy Agents Market Size, Share & Trends Analysis Report By Product Type (Reactive Agents, Contrast Agents, Absorptive Agents), By Application (Gastrointestinal Diseases, Colorectal Diseases, Esophageal Diseases, Others), By End-User (Hospitals, Diagnostic Laboratories, Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global chromoendoscopy agents market size was valued at USD 126 million in 2022 and is projected to reach USD 175 million by 2031, registering a CAGR of 4.2% during the forecast period (2023-2031). Factors such as improved detection of abnormalities and technological advancement, significantly drives the chromoendoscopy agents market demand by 2031.

The increasing adoption of new diagnostic procedures and growing knowledge about the benefits of chromoendoscopy in diagnosing gastrointestinal problems stimulate market growth. Chromoendoscopy agents are compounds used during chromoendoscopy treatments to improve the visualization of tissues and abnormalities in the gastrointestinal tract. Chromoendoscopy is a procedure used by medical experts, namely gastroenterologists, to increase the detection and characterization of numerous G.I. diseases, such as polyps, inflammation, and early cancer indications.

The chromoendoscopy agents Market share is expected to grow at 4.2% CAGR because of the increasing adoption of new diagnostic procedures and growing knowledge about the benefits of chromoendoscopy in diagnosing gastrointestinal problems. Early identification is the key to good therapy and clinical outcomes in cancer and malignancy. Endoscopy can quickly detect gastric and colorectal cancer. Traditional endoscopy, on the other hand, has difficulty in detecting tiny lesions, which raises the miss rate.

Market Dynamics

Chromoendoscopy agents market drivers

Improved detection of abnormalities

Chromoendoscopy agents increase the contrast between normal and pathological tissue, making it simpler for healthcare practitioners to detect subtle changes such as precancerous lesions, polyps, and inflammatory disorders that white light endoscopy may miss. Colorectal polyps are common precancerous lesions. Early detection and removal of these polyps can greatly minimize the risk of cancer development. Chromoendoscopy, particularly with indigo carmine dye, increases the detection of flat or inconspicuous polyps that might otherwise go undetected during standard endoscopy.

The chromoendoscopy agents market trend is being boosted by Detecting anomalies at an early stage, allowing for timely intervention and therapy, which can prevent benign disorders from progressing to malignancies such as colorectal cancer. Improved visualization improves effective diagnosis, lowering the likelihood of overlooked or misdiagnosed abnormalities.

Chromoendoscopy agents market restraints

Lack of awareness and training

Chromoendoscopy is a sophisticated method requiring healthcare professionals to understand its principles, applications, and proper implementation completely. Despite their potential benefits, chromoendoscopy chemicals may be used ineffectively due to a lack of understanding and training among medical practitioners. Adequate training reduces the likelihood of errors in applying agents and interpreting improved images. This is critical for appropriate diagnosis and treatment decisions. Gastroenterologists are frequent users of chromoendoscopy agents to detect problems in the gastrointestinal tract.

However, the effective application of these agents necessitates specific expertise. Gastroenterologists must learn how to prepare and administer the agents, analyze the improved images, and make appropriate diagnoses based on the visual signals offered by the agents. As a result, it impedes the expansion of the Chromoendoscopy agents market.

Chromoendoscopy agents market opportunity

Technological advancement

Medical technological advancements, particularly in endoscopy procedures and imaging modalities, present a great opportunity to improve the effectiveness and use of chromoendoscopy agents. Endoscopy technology improvements have resulted in integrating advanced imaging modalities with chromoendoscopy. For example, narrow-band imaging (NBI) improves the imaging of mucosal structures and vascular patterns. When used with chromoendoscopy agents, NBI can provide more detailed and accurate information on the gastrointestinal tract's status.

Advanced imaging modalities enhance the clarity and detail of chromoendoscopy-enhanced pictures, making it easier to detect small abnormalities. As technology advances, there will be more chances to combine chromoendoscopy with cutting-edge imaging modalities like confocal laser endomicroscopy and virtual reality-enhanced visualization. These advancements can give real-time microscopic vision and three-dimensional reconstructions of the gastrointestinal mucosa, further boosting diagnostic capabilities.

Regional Analysis

the global chromoendoscopy agents market share is bifurcated into north america, europe, asia-pacific, the middle east and africa, and latin america.

North America holds a sizeable global market share and is expected to boost at a CAGR of 4.5% during the forecast period. The primary drivers of market expansion include rising demand for sophisticated diagnostic equipment, advantageous health reimbursement, and increased endoscopic procedures. North America, including the United States and Canada, has an advanced healthcare system and a high prevalence of gastrointestinal problems. Because of the emphasis on early disease identification and innovative medical technologies, the use of chromoendoscopy agents is well-established in the region. Colorectal cancer is the third most prevalent cancer diagnosed in both men and women in the United States, according to the American Cancer Society. An estimated 149,500 new cases of colorectal cancer were predicted to be diagnosed in the United States in 2022.

Furthermore, the Centers for Disease Control and Prevention (CDC) projected that in 2020, around 68.8% of persons aged 50 to 75 in the United States had completed colorectal cancer screening. North American regulatory bodies, such as the United States Food and Drug Administration (FDA) and Health Canada, play a role in authorizing and regulating medical devices, including chromoendoscopy agents, to ensure their safety and efficacy. Chromoendoscopy agents Market insights suggest that, with an emphasis on improving patient outcomes through early disease detection and precise diagnosis, the market is expected to grow steadily.

Europe is predicted to rise at a substantial CAGR of 4.3% throughout the forecast period. The market in Europe is expected to grow because of the increased prevalence of cancer. According to WHO, the incidence of colon cancer in Europe is expected to reach 349,000 by 2025. This is projected to boost the European market. Europe is noted for having modern healthcare systems, a strong emphasis on medical research, and a high prevalence of gastrointestinal illnesses. These characteristics contribute to the acceptance of novel diagnostic procedures such as chromoendoscopy.

The European market for chromoendoscopy agents demonstrates the region's dedication to early disease identification and enhanced patient care. The vibrant research community in Europe actively contributes to developing new chromoendoscopy agents and procedures, promoting chromoendoscopy agents market growth through innovation. Medical devices, particularly chromoendoscopy agents, are subject to stringent regulatory criteria, which promote trust and adoption among healthcare professionals.

The Asia-Pacific market is expected to increase significantly due to an aging population and technological advancements. The Asia-Pacific region's healthcare scene is diversified, with significant technology breakthroughs and a growing burden of gastrointestinal disorders. As the region's healthcare systems evolve, innovative diagnostic techniques such as chromoendoscopy agents offer substantial growth potential. Stomach cancer is one of the top causes of cancer-related fatalities in Asia, according to the International Agency for Research on Cancer (IARC). Stomach cancer rates are significantly higher in some places, such as Eastern Asia. South Korea, for example, has one of the highest rates of stomach cancer incidence globally. The Asia-Pacific region is plagued by gastrointestinal disorders such as stomach cancer, colorectal cancer, and hepatitis-related conditions. This increases the requirement for precise diagnostic techniques such as chromoendoscopy agents.

The market in Latin America, the Middle East and Africa is expected to increase due to strong government support for healthcare worker training and building health infrastructure. Colorectal cancer is one of the top causes of cancer-related fatalities in Latin America, according to the International Agency for Research on Cancer (IARC). For example, colorectal cancer is one of Brazil's most often diagnosed diseases. The Brazilian National Cancer Institute (INCA) predicts that approximately 40,000 new instances of colorectal cancer will be diagnosed in Brazil by 2020.

Segmental Analysis

the global chromoendoscopy agents market is segmented based on product type, application, end-user.

By Product type is further segmented into Reactive, Contrast, and Absorptive Agents.

Absorptive Agents hold the major market share. Absorptive agents are topically administered to the mucosal surface and absorbed by the tissue. These agents improve the contrast between normal and diseased tissue by altering the appearance of the tissue under endoscopy. Absorptive agents can assist in identifying regions of inflammation, dysplasia, and other abnormalities. Reactive agents are chemicals that interact chemically with the mucosa of the gastrointestinal tract. These chemicals can expose specific traits or disorders through color changes or interactions with certain tissue components. Reactive agents improve the visibility of mucosal patterns and minor abnormalities.

The segment can be bifurcated by application into Gastrointestinal Diseases, Colorectal Diseases, Esophageal Diseases, and Others.

Colorectal Diseases is the highest contributor to the market. Anomalies in the colon and rectum characterize colorectal diseases. Colorectal cancer, adenomatous polyps (precursors to colorectal cancer), diverticular disease, and other colorectal diseases are included in this sub-category. Colorectal disease diagnosis, characterization, and surveillance rely heavily on chromoendoscopy agents. This sub-category includes many gastrointestinal ailments and disorders, such as Crohn's disease and ulcerative colitis, gastritis, peptic ulcers, and other non-specific mucosal abnormalities. Chromoendoscopy agents can help healthcare workers comprehend the breadth and severity of mucosal alterations, assisting in diagnosing and monitoring these disorders.

The market is segmented based on end-users into Hospitals, diagnostic laboratories, clinics, and others.

Hospitals influenced the Chromoendoscopy Agents Market growth.

Hospitals represent a sizable end-user market for chromoendoscopy agents. To diagnose and treat diverse gastrointestinal problems, hospitals perform a wide range of medical procedures, including endoscopy. Chromoendoscopy agents are used in hospitals to increase diagnostic accuracy, aid in treatment planning, and improve patient outcomges. Diagnostic laboratories play an important role in the processing and analysis of endoscopic samples. Tissue samples, biopsies, and other specimens collected with chromoendoscopy procedures are handled in these laboratories. An accurate examination of these samples is required for correct diagnosis.

Recent Developments

• June 2023- Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ("Cosmo") announced that its partner Ferring Pharmaceuticals ("Ferring") has gained Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for Cortiment® (budesonide 9 mg MMX tablets). Cortiment® sales in Japan are planned to begin by the end of the third quarter of 2023.
• July 2023- Merck invested 23 million Euros in Kansas, USA, to expand cell culture media production.
• August 2023- Thermo Fisher Scientific introduced the EXENT® solution with IVDR Certification.
• August 2023- Thermo Fisher Scientific launched a new chromosomal microarray with a two-day turnaround time to boost lab productivity.